Simplified HIV Testing and Treatment in China: Analysis of Mortality Rates Before and After a Structural Intervention

Wu, Zunyou; Zhao, Yan; Ge, Xianmin; Mao, Yurong; Tang, Zhenzhu; Shi, Cynthia X.; Chen, Chi; Li, Yong; Qiu, Xuejun; Nong, Guide; Huang, Shanhui; Luo, Shen; Wu, Shaohui; He, Wenzhen; Zhang, Mingjie; Shen, Zhiyong; Jin, Xia; Li, Jian; Brookmeyer, Ron; Detels, Roger
September 2015
PLoS Medicine;9/8/2015, Vol. 12 Issue 9, p1
Academic Journal
Background: Multistage stepwise HIV testing and treatment initiation procedures can result in lost opportunities to provide timely antiretroviral therapy (ART). Incomplete patient engagement along the continuum of HIV care translates into high levels of preventable mortality. We aimed to evaluate the ability of a simplified test and treat structural intervention to reduce mortality. Methods and Findings: In the “pre-intervention 2010” (from January 2010 to December 2010) and “pre-intervention 2011” (from January 2011 to December 2011) phases, patients who screened HIV-positive at health care facilities in Zhongshan and Pubei counties in Guangxi, China, followed the standard-of-care process. In the “post-intervention 2012” (from July 2012 to June 2013) and “post-intervention 2013” (from July 2013 to June 2014) phases, patients who screened HIV-positive at the same facilities were offered a simplified test and treat intervention, i.e., concurrent HIV confirmatory and CD4 testing and immediate initiation of ART, irrespective of CD4 count. Participants were followed for 6–18 mo until the end of their study phase period. Mortality rates in the pre-intervention and post-intervention phases were compared for all HIV cases and for treatment-eligible HIV cases. A total of 1,034 HIV-positive participants (281 and 339 in the two pre-intervention phases respectively, and 215 and 199 in the two post-intervention phases respectively) were enrolled. Following the structural intervention, receipt of baseline CD4 testing within 30 d of HIV confirmation increased from 67%/61% (pre-intervention 2010/pre-intervention 2011) to 98%/97% (post-intervention 2012/post-intervention 2013) (all p < 0.001 [i.e., for all comparisons between a pre- and post-intervention phase]), and the time from HIV confirmation to ART initiation decreased from 53 d (interquartile range [IQR] 27–141)/43 d (IQR 15–113) to 5 d (IQR 2–12)/5 d (IQR 2–13) (all p < 0.001). Initiation of ART increased from 27%/49% to 91%/89% among all cases (all p < 0.001) and from 39%/62% to 94%/90% among individuals with CD4 count ≤ 350 cells/mm3 or AIDS (all p < 0.001). Mortality decreased from 27%/27% to 10%/10% for all cases (all p < 0.001) and from 40%/35% to 13%/13% for cases with CD4 count ≤ 350 cells/mm3 or AIDS (all p < 0.001). The simplified test and treat intervention was significantly associated with decreased mortality rates compared to pre-intervention 2011 (adjusted hazard ratio [aHR] 0.385 [95% CI 0.239–0.620] and 0.380 [95% CI 0.233–0.618] for the two post-intervention phases, respectively, for all newly diagnosed HIV cases [both p < 0.001], and aHR 0.369 [95% CI 0.226–0.603] and 0.361 [95% CI 0.221–0.590] for newly diagnosed treatment-eligible HIV cases [both p < 0.001]). The unit cost of an additional patient receiving ART attributable to the intervention was US$83.80. The unit cost of a death prevented because of the intervention was US$234.52. Conclusions: Our results demonstrate that the simplified HIV test and treat intervention promoted successful engagement in care and was associated with a 62% reduction in mortality. Our findings support the implementation of integrated HIV testing and immediate access to ART irrespective of CD4 count, in order to optimize the impact of ART.


Related Articles

  • Overcoming the Barriers to Timely Antiretroviral Initiation in HIV-Infected Infants. Sturt, Amy; Troy, Stephanie B. // Journal of Tropical Pediatrics;Aug2014, Vol. 60 Issue 4, p267 

    No abstract available.

  • Reduction of Maternal Mortality with Highly Active Antiretroviral Therapy in a Large Cohort of HIV-Infected Pregnant Women in Malawi and Mozambique. Liotta, Giuseppe; Mancinelli, Sandro; Nielsen-Saines, Karin; Gennaro, E.; Scarcella, Paola; Magid, Nurja Abdul; Germano, Paola; Jere, Haswell; Guidotti, Gianni; Buonomo, Ersilia; Ciccacci, Fausto; Palombi, Leonardo; Marazzi, Maria Cristina // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Background: HIV infection is a major contributor to maternal mortality in resource-limited settings. The Drug Resource Enhancement Against AIDS and Malnutrition Programme has been promoting HAART use during pregnancy and postpartum for Prevention-of-mother-to-child-HIV transmission (PMTCT)...

  • Are there benefits to starting antiretroviral therapy during primary HIV infection? Conclusions from the Seattle Primary Infection Cohort vary by control group. Stekler, J. D.; Wellman, R.; Holte, S.; Maenza, J.; Stevens, C. E.; Corey, L.; Collier, A. C. // International Journal of STD & AIDS;Mar2012, Vol. 23 Issue 3, p201 

    It is controversial whether starting combination antiretroviral therapy (cART) during primary HIV infection (PHI) is beneficial. Subjects in this observational cohort began cART <30 days (group 1: acute treatment, n = 40), 31-180 days (group 2: early treatment, n = 82) or >180 days (group 3:...

  • Shifting our focus to HIV as a chronic disease. Hickner, John // Journal of Family Practice;Jul2014, Vol. 63 Issue 7, p355 

    The author reflects on the evolution of diagnosis and treatment of HIV infections. Topics discussed by the author include discovery of highly active antiretroviral therapy (HAART) which has transformed HIV and AIDS to a chronic primary care disease from an acute and infectious disease, the...

  • Provision of Antiretroviral Therapy for HIV-Positive TB Patients -- 19 Countries, Sub-Saharan Africa, 2009-2013. Dokubo, E. Kainne; Baddeley, Annabel; Pathmanathan, Ishani; Coggin, William; Firth, Jacqueline; Getahun, Haileyesus; Kaplan, Jonathan; Date, Anand // MMWR: Morbidity & Mortality Weekly Report;11/28/2014, Vol. 63 Issue 47, p1104 

    The article discusses research which examined the progress in provision of antiretroviral therapy (ART) to patients with human immunodeficiency virus (HIV) infections and tuberculosis (TB) in sub-Saharan African countries in 2009-2013. Topics covered include the increase in ART coverage among...

  • Vital Signs: HIV Diagnosis, Care, and Treatment Among Persons Living with HIV -- United States, 2011. Bradley, Heather; Hall, H. Irene; Wolitski, Richard J.; Van Handel, Michelle M.; Stone, Amy E.; LaFlam, Michael; Skarbinski, Jacek; Higa, Darrel H.; Prejean, Joseph; Frazier, Emma L.; Patel, Roshni; Ping Huang; Qian An; Ruiguang Song; Tian Tang; Valleroy, Linda A. // MMWR: Morbidity & Mortality Weekly Report;11/28/2014, Vol. 63 Issue 47, p1113 

    Background: Infection with human immunodeficiency virus (HIV), if untreated, leads to acquired immunodeficiency syndrome (AIDS) and premature death. However, a continuum of services including HIV testing, HIV medical care, and antiretroviral therapy (ART) can lead to viral suppression, improved...

  • Patient Enrolment into HIV Care and Treatment within 90 Days of HIV Diagnosis in Eight Rwandan Health Facilities: A Review of Facility-Based Registers. Kayigamba, Felix R.; Bakker, Mirjam I.; Fikse, Hadassa; Mugisha, Veronicah; Asiimwe, Anita; Loeff, Maarten F. Schim van der // PLoS ONE;May2012, Vol. 7 Issue 5, p1 

    Introduction: Access to antiretroviral therapy (ART) has increased greatly in sub-Saharan Africa. However many patients do not enrol timely into HIV care and treatment after HIV diagnosis. We studied enrolment into care and treatment and determinants of non-enrolment in Rwanda. Methods: Data...

  • Wood smoke raises COPD risk.  // Clinical Advisor;Sep2010, Vol. 13 Issue 9, p16 

    The article reports on the updated guidelines presented by an international panel for HIV antiretroviral therapy (ART). According to the new guidelines, a decision to use ART needs the assessment of morbidity and mortality-related advantages of the treatment over therapy risks such as drug...

  • HAART may be effective for HIV epidemic control.  // PharmacoEconomics & Outcomes News;7/24/2010, Issue 608, p4 

    The article discusses research study on the association of highly active antiretroviral therapy, coverage, population viral load and yearly new human immunodeficiency virus (HIV) diagnoses in British Columbia, referencing a study by J. S. G. Montaner and colleagues published in the July 18, 2010...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics